These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 29233295)

  • 1. Novel approaches to targeting BRD4.
    Kharenko OA; Hansen HC
    Drug Discov Today Technol; 2017 Jun; 24():19-24. PubMed ID: 29233295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bromodomain Drug Discovery - the Past, the Present, and the Future.
    Pervaiz M; Mishra P; Günther S
    Chem Rec; 2018 Dec; 18(12):1808-1817. PubMed ID: 30289209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting BET bromodomains for cancer treatment.
    Jung M; Gelato KA; Fernández-Montalván A; Siegel S; Haendler B
    Epigenomics; 2015; 7(3):487-501. PubMed ID: 26077433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries.
    Wang B; Zhang M; Takayama T; Shi X; Roenneburg DA; Kent KC; Guo LW
    EBioMedicine; 2015 Nov; 2(11):1650-61. PubMed ID: 26870791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-based protein stabilization assays for the detection of interactions between small-molecule inhibitors and BRD4.
    Schulze J; Moosmayer D; Weiske J; Fernández-Montalván A; Herbst C; Jung M; Haendler B; Bader B
    J Biomol Screen; 2015 Feb; 20(2):180-9. PubMed ID: 25266565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors.
    Ramadoss M; Mahadevan V
    Drug Discov Today; 2018 Jan; 23(1):76-89. PubMed ID: 28943305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
    Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
    Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and Characterization of Novel Covalent Bromodomain and Extra-Terminal Domain (BET) Inhibitors Targeting a Methionine.
    Kharenko OA; Patel RG; Brown SD; Calosing C; White A; Lakshminarasimhan D; Suto RK; Duffy BC; Kitchen DB; McLure KG; Hansen HC; van der Horst EH; Young PR
    J Med Chem; 2018 Sep; 61(18):8202-8211. PubMed ID: 30165024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phospho-BRD4: transcription plasticity and drug targeting.
    Chiang CM
    Drug Discov Today Technol; 2016 Mar; 19():17-22. PubMed ID: 27769352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor.
    Zhao Y; Zhou B; Bai L; Liu L; Yang CY; Meagher JL; Stuckey JA; McEachern D; Przybranowski S; Wang M; Ran X; Aguilar A; Hu Y; Kampf JW; Li X; Zhao T; Li S; Wen B; Sun D; Wang S
    J Med Chem; 2018 Jul; 61(14):6110-6120. PubMed ID: 30015487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-terminal Domain (BET) Proteins.
    Raux B; Voitovich Y; Derviaux C; Lugari A; Rebuffet E; Milhas S; Priet S; Roux T; Trinquet E; Guillemot JC; Knapp S; Brunel JM; Fedorov AY; Collette Y; Roche P; Betzi S; Combes S; Morelli X
    J Med Chem; 2016 Feb; 59(4):1634-41. PubMed ID: 26735842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and structure-activity relationship studies of N6-benzoyladenine derivatives as novel BRD4 inhibitors.
    Noguchi-Yachide T; Sakai T; Hashimoto Y; Yamaguchi T
    Bioorg Med Chem; 2015 Mar; 23(5):953-9. PubMed ID: 25678016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins - A review.
    Yang CY; Qin C; Bai L; Wang S
    Drug Discov Today Technol; 2019 Apr; 31():43-51. PubMed ID: 31200858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel coumarin derivatives as potent and orally bioavailable BRD4 inhibitors based on scaffold hopping.
    Zhang Z; Gu L; Wang B; Huang W; Zhang Y; Ma Z; Zeng S; Shen Z
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):808-817. PubMed ID: 30879350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disrupting Acetyl-lysine Interactions: Recent Advance in the Development of BET Inhibitors.
    Zhang F; Ma S
    Curr Drug Targets; 2018; 19(10):1148-1165. PubMed ID: 29189147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging roles of and therapeutic strategies targeting BRD4 in cancer.
    White ME; Fenger JM; Carson WE
    Cell Immunol; 2019 Mar; 337():48-53. PubMed ID: 30832981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
    Mirguet O; Gosmini R; Toum J; Clément CA; Barnathan M; Brusq JM; Mordaunt JE; Grimes RM; Crowe M; Pineau O; Ajakane M; Daugan A; Jeffrey P; Cutler L; Haynes AC; Smithers NN; Chung CW; Bamborough P; Uings IJ; Lewis A; Witherington J; Parr N; Prinjha RK; Nicodème E
    J Med Chem; 2013 Oct; 56(19):7501-15. PubMed ID: 24015967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of BRD4 bromodomain inhibitors by fragment-based high-throughput docking.
    Zhao H; Gartenmann L; Dong J; Spiliotopoulos D; Caflisch A
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2493-6. PubMed ID: 24767840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
    Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
    Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4.
    Allen BK; Mehta S; Ember SW; Schonbrunn E; Ayad N; Schürer SC
    Sci Rep; 2015 Nov; 5():16924. PubMed ID: 26596901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.